Skip directly to content

Inlyta®

Inlyta® is a second line oral therapy that targets VEGF receptor-related renal cell abnormalities1. Inlyta® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.

 

Reference:

  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
  2. Safety Net. HA Drug Formulary Management.  Accessed on 8 August 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: